Related Experiment Video
Updated: Jul 30, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Cyclooxygenase-2 in hepatocellular carcinoma
1Department of Pathology, University of Pittsburgh School of Medicine, MUH E-740, 200 Lothrop Street, Pittsburgh, PA 15213, USA. wut@upmc.edu
Cancer Treatment Reviews
|December 13, 2005
Summary
Hepatocellular carcinoma (HCC) research shows cyclooxygenase-2 (COX-2) signaling drives cancer growth. Targeting COX-2 and related pathways may offer new treatments for this deadly liver cancer.
Area of Science:
- Hepatocellular carcinoma (HCC) research
- Cancer biology and signaling pathways
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally, with rising incidence and limited effective treatments.
- Cyclooxygenase-2 (COX-2) signaling is implicated in liver cancer development, and COX-2 inhibitors show promise in preclinical models.
- Concerns regarding side effects of some COX-2 inhibitors necessitate alternative or combination therapeutic strategies.
Purpose of the Study:
- To review recent advances in understanding COX-2 signaling in hepatocarcinogenesis.
- To focus on the interactions between prostaglandin (PG) cascade and other key signaling pathways regulating HCC growth.
- To highlight the potential for developing improved chemopreventive and therapeutic strategies for HCC.
Main Methods:
- Literature review of recent scientific evidence on COX-2 signaling in hepatocarcinogenesis.
- Analysis of the interplay between COX-2-derived PG signaling and other growth-regulatory pathways (e.g., EGFR, Met, iNOS, VEGF, n-3 polyunsaturated fatty acids).
- Synthesis of current understanding to identify therapeutic implications.
Main Results:
- COX-2 signaling is a significant factor in liver cancer initiation and progression.
- Novel interactions between the prostaglandin cascade and pathways like EGFR, Met, iNOS, VEGF, and n-3 PUFAs have been identified.
- These interplays suggest potential for synergistic anti-tumor effects when targeting multiple pathways.
Conclusions:
- Combinational therapeutic approaches targeting COX-2 and other key molecules, or combining COX-2 inhibitors with standard therapies, may offer synergistic benefits with reduced side effects.
- Understanding the complex signaling network involving COX-2 is crucial for developing more effective chemopreventive and therapeutic strategies for HCC.
- Further research into these interactions holds significant promise for improving outcomes in patients with liver cancer.
Related Concept Videos
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:24Peroxisomes
Peroxisomes are specialized organelles present in fungi, plant, and animal cells. It can vary in number, size, morphology, and activity depending on the type of tissue and the nutritional state of the cell. For example, cells with active lipid metabolism, such as adipocytes, neurons, and hepatocytes, have more peroxisomes than other cells in the body. Besides their primary role in breaking down complex organic molecules, peroxisomes can also synthesize specific macromolecules and participate in...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...